Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. - Louveau B; Resche-Rigon M; Lesimple T; Da Meda L; Pracht M; Baroudjian B; Delyon J; Amini-Adle M; Dutriaux C; Reger de Moura C; Sadoux A; Jouenne F; et al. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2021)